000132629 001__ 132629
000132629 005__ 20240229105024.0
000132629 0247_ $$2doi$$a10.1016/j.ctrv.2018.02.003
000132629 0247_ $$2pmid$$apmid:29459248
000132629 0247_ $$2ISSN$$a0305-7372
000132629 0247_ $$2ISSN$$a1532-1967
000132629 0247_ $$2altmetric$$aaltmetric:34729495
000132629 037__ $$aDKFZ-2018-00289
000132629 041__ $$aeng
000132629 082__ $$a610
000132629 1001_ $$0P:(DE-He78)657300dfd28903ec8149ca9bf5e7968d$$aBoakye, Daniel$$b0$$eFirst author$$udkfz
000132629 245__ $$aImpact of comorbidity and frailty on prognosis in colorectal cancer patients: A systematic review and meta-analysis.
000132629 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2018
000132629 3367_ $$2DRIVER$$aarticle
000132629 3367_ $$2DataCite$$aOutput Types/Journal article
000132629 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659527058_29252$$xReview Article
000132629 3367_ $$2BibTeX$$aARTICLE
000132629 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132629 3367_ $$00$$2EndNote$$aJournal Article
000132629 520__ $$aColorectal cancer (CRC) is largely diagnosed at old age, when comorbidities and frailty are common and might be important prognostic factors of CRC. We aimed to systematically review epidemiological evidence on the prognostic role of comorbidity and frailty in CRC patients.We systematically searched the PubMed and Web of Science databases up to August 08, 2017 for observational studies that used a standardized index to assess comorbidity or frailty, investigated and reported odds ratios (OR) or hazard ratios (HR) of their associations with any of the following CRC prognostic outcomes: thirty-day, overall or CRC-specific mortality and disease-free or recurrence-free survival. The study was conducted using standard meta-analysis methodology.Thirty-seven cohort studies were identified and included in this review: 35 on comorbidity and 2 on frailty. Of the 35 studies, 13 with comparable methodology were eligible for a meta-analysis. Compared to CRC patients without comorbidity, those with mild/moderate and severe comorbidity had, respectively, a higher risk of 30-day (OR = 1.71; 95% confidence interval (CI): 1.26-2.31 and OR = 2.62; 95% CI: 1.97-3.47), overall (HR = 1.41; 95% CI: 1.23-1.62 and HR = 2.03; 95% CI: 1.76-2.34), and CRC-specific mortality (HR = 1.06; 95% CI: 1.02-1.10 and HR = 1.14; 95% CI: 1.04-1.23). Frail CRC patients showed higher overall mortality than non-frail patients (HRrange: 2.60-3.39).Comorbidity and frailty are strong prognostic factors of survival in CRC patients apart from the commonly considered sociodemographic and tumor characteristics. Comprehensive geriatric assessment might help to optimize care of CRC patients, by improving early identification and management of comorbidities and geriatric syndromes.
000132629 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000132629 588__ $$aDataset connected to CrossRef, PubMed,
000132629 7001_ $$0P:(DE-HGF)0$$aRillmann, Bettina$$b1
000132629 7001_ $$0P:(DE-He78)6c2a1ea8cce3580fe2d1c1df120a92b9$$aWalter, Viola$$b2$$udkfz
000132629 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b3$$udkfz
000132629 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b4$$udkfz
000132629 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b5$$eLast author$$udkfz
000132629 773__ $$0PERI:(DE-600)2002084-3$$a10.1016/j.ctrv.2018.02.003$$gVol. 64, p. 30 - 39$$p30 - 39$$tCancer treatment reviews$$v64$$x0305-7372$$y2018
000132629 909CO $$ooai:inrepo02.dkfz.de:132629$$pVDB
000132629 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)657300dfd28903ec8149ca9bf5e7968d$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000132629 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132629 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c2a1ea8cce3580fe2d1c1df120a92b9$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000132629 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000132629 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000132629 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000132629 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000132629 9141_ $$y2018
000132629 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000132629 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER TREAT REV : 2015
000132629 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132629 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132629 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132629 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132629 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132629 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132629 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132629 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132629 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000132629 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings
000132629 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER TREAT REV : 2015
000132629 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000132629 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000132629 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000132629 980__ $$ajournal
000132629 980__ $$aVDB
000132629 980__ $$aI:(DE-He78)C070-20160331
000132629 980__ $$aI:(DE-He78)G110-20160331
000132629 980__ $$aI:(DE-He78)L101-20160331
000132629 980__ $$aUNRESTRICTED